论文部分内容阅读
哮喘是儿童期常见的以气道炎症为特征的异质性呼吸道疾病，部分患儿经常规治疗仍不能控制。随着哮喘发病机制及内表型的研究进展，目前针对T2型哮喘的靶向药物奥马珠单抗、美泊利单抗、贝那利单抗及度普利尤单抗已在部分年龄段儿童患者中批准应用并取得了良好的疗效，成为重症及难治性哮喘儿童的新希望。但非T2型哮喘尚缺乏有效的靶向药物。为广大临床工作者更好地应用这类药物，该文对近年来儿童哮喘靶向药物的研究进展进行综述。“,”Asthma is a heterogeneous respiratory disorder characterized by airway inflammation that is common in childhood, and some children cannot be controlled with conventional treatment.With the progress on the pathogenesis and endotypes of asthma, targeted agents for T2 asthma, such as omalizumab, mepolizumab, benralizumab and dupilumab have been approved prescripting in pediatric patients of some ages and have achieved good efficacy, becoming the new hope for children with severe and refractory asthma.However, there is a lack of effective targeted medicines for non-T2 asthma.This paper reviews the progress of targeted agents for childhood asthma in recent years for the better application of such drugs by clinical practitioners.